----item----
version: 1
id: {6D3CB7F3-FA22-497D-88DE-B105E8E1228B}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/06/05/Sorin Biomedicas cardiology sales ride healthcare budget cuts
parent: {D0EEB970-226B-4F71-9D71-89421483D0F4}
name: Sorin Biomedicas cardiology sales ride healthcare budget cuts
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: c6a6527b-caea-4987-8f2c-2ead0eed3e38

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 365

<p>Sorin Biomedica's cardiology sales rose 6.2% to Lit 453 billion ($273 million) in 1994, according to the company's annual report. They were up 11% on a comparative basis. According to the sales breakdown, turnover by the diagnostics division remained virtually static - up just 0.4% at Lit 217 billion, while haemodialysis sales rose 8.4% to Lit 167 billion.</p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 62

Sorin Biomedica's cardiology sales ride healthcare budget cuts
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 3259

<p>Sorin Biomedica's cardiology sales rose 6.2% to Lit 453 billion ($273 million) in 1994, according to the company's annual report. They were up 11% on a comparative basis. According to the sales breakdown, turnover by the diagnostics division remained virtually static - up just 0.4% at Lit 217 billion, while haemodialysis sales rose 8.4% to Lit 167 billion.</p><p>The breakdown of sales (domestic and international) for each of these business areas is as follows:</p><pre>(Amounts in Lit billions) Sales abroad Sales in Italy 1994 1993 1994 1993 Cardiology 338 323 115 103 Diagnostics 136 127 81 88 Haemodialysis 65 59 103 96</pre><p>The pressures of the Italian market forced prices and consumption down, Sorin notes in the report, although this was more evident with diagnostics than life-saving products. Cost- containment controls were even more stringent in 1994 than in the preceding year.</p><p>reshaping the group</p><p>Sorin Biomedica SpA is now the holding company for the group. Each of the group's business sectors has a managing company - Dideco for cardiology, Bellco for haemodialysis and Sorin Biomedica Diagnostics for diagnostics. These companies co- ordinate manufacturing and distribution businesses worldwide. (Sorin Biomedica Cardio, formed at the end of 1993, is 100%- owned by Dideco).</p><p>Cardiology</p><p>1994 highlights within the group's cardiology sector included:</p><p>* the launch of a new cardiopulmonary system;</p><p>* the relaunch of the apheresis business with greater emphasis in the US autotransfusion market;</p><p>* US manufacture of the Monolith external blood oxygenator;</p><p>* the launch of new miniaturised pacemakers;</p><p>* the signing of an agreement with Cardiac Pathways Corp for the development and manufacture of cardiac catheters; and</p><p>* the completion of a biomaterials factory in Brindisi.</p><p>Haemodialysis</p><p>Notable events during 1994 in haemodialysis included:</p><p>* the production of filters employing a range of new generation fibres; and</p><p>* work began on the new "Multimat" machine, which should be more cost-effective.</p><p>Diagnostics</p><p>Within the diagnostics sector, the group:</p><p>* renewed and reinforced its ELISA range of products, with particular focus on hepatitis and AIDS;</p><p>* introduced new antibody kits for autoimmune thyroid diseases;</p><p>* introduced non-isotopic markers for prostate and gastrointestinal tumours;</p><p>* arranged to distribute Centocor's lung cancer RIA;</p><p>* obtained Italian Ministry of Health premarket approval for its new hepatitis C test;</p><p>* launched new infectious disease blood tests developed by Incstar (US) in Europe; and</p><p>* introduced a new technetium tracer for nuclear cardiology.</p><p>overall results</p><p>As reported in Clinica No 648, p 13, group sales were up 5.1% (7% on a comparable basis) to Lit 837 billion, of which 64% were accounted for abroad. Net income, meanwhile, was Lit 38.7 billion in 1994 compared with Lit 63 billion in 1993 when the tracheostomy business was sold. On a comparable basis income was up 50%, the company told Clinica. Spending on R&D totalled Lit 53,200 million in 1994, or 6.4% of turnover, compared with Lit 54,100 million, or 6.8% of turnover, in 1993.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{2E0CEEF8-031D-43E8-B6AA-07D1397D9E4F}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 61

Sorin Biomedicas cardiology sales ride healthcare budget cuts
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950605T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950605T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950605T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT052934
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 62

Sorin Biomedica's cardiology sales ride healthcare budget cuts
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

254743
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184333Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

c6a6527b-caea-4987-8f2c-2ead0eed3e38
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184333Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
